<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1061">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04483635</url>
  </required_header>
  <id_info>
    <org_study_id>MP-21-2021-3044</org_study_id>
    <nct_id>NCT04483635</nct_id>
  </id_info>
  <brief_title>PRevention of COVID-19 With Oral Vitamin D Supplemental Therapy in Essential healthCare Teams</brief_title>
  <acronym>PROTECT</acronym>
  <official_title>PROTECT RCT (PRevention of COVID-19 With Oral Vitamin D Supplemental Therapy in Essential healthCare Teams</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Justine's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Canadian Institutes of Health Research (CIHR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Laboratoire RIVA</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>St. Justine's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this 16-week randomized control study, health care workers will receive a bolus dose&#xD;
      followed by a weekly dose of vitamin D or a placebo bolus and weekly dose. This study will&#xD;
      test whether high-dose of vitamin D supplementation decreases the incidence of&#xD;
      laboratory-confirmed COVID19 infection (primary outcome), reduces illness severity, duration,&#xD;
      as well as work absenteeism among health care workers (HCW) in setting at high-risk of&#xD;
      contact with COVID-19 cases in high COVID-19 incidence areas.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Design. A 16-week triple-blind, placebo-controlled parallel-group, randomised trial of&#xD;
      high-dose vitamin D supplementation compared to placebo in health care workers (HCW).&#xD;
&#xD;
      Subjects: HCW caring for individuals at high-risk of infection (i.e., COVID-suspected or&#xD;
      confirmed cases) will be randomly allocated in a 1:1 ratio in variable block size to:&#xD;
      Intervention-1 oral loading dose of 100,000 IU vitamin D3 + 10000 IU weekly vitamin D3 or&#xD;
      Control-identical placebo loading dose + daily placebo. Follow-up: 2 (randomisation and&#xD;
      end-of-study) virtual or in-person visits with weekly reminders, brief health and work-status&#xD;
      questionnaire, and repeated salivary (or nasopharyngeal) samples.&#xD;
&#xD;
      Randomisation/allocation concealment: Randomisation will be implemented using a&#xD;
      computer-generated random list stratified by regions; health care workers will be allocated&#xD;
      (1:1) using permuted block randomisation to enhance concealment.&#xD;
&#xD;
      Sample size: A total of 2414 healthcare workers will provide 80% power to detect a 20%&#xD;
      reduction in the risk of laboratory-confirmed COVID-19 infection. Given uncertainties in the&#xD;
      infection progression, a Bayesian adaptive design is used where the posterior probability of&#xD;
      effectiveness is the basis of inference and decision making, for study continuation or&#xD;
      termination.&#xD;
&#xD;
      Procedures. Use of remote or in-person randomisation and/or end-of-study visits and remote&#xD;
      documentation of outcomes via electronic communication, mailing of biological samples, and&#xD;
      external databases will facilitate enrolment, monitoring, and retention of motivated HCW in&#xD;
      this high-intensity trial.&#xD;
&#xD;
      Data analyses: An intention-to-treat analysis will be carried out on all randomized&#xD;
      participants. Efficacy and safety analyses will be performed under allocation concealment&#xD;
      with unblinding occurring after trial completion and analysis of primary outcomes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 30, 2020</start_date>
  <completion_date type="Anticipated">June 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Parallel-group, placebo controlled trial of vitamin D3 supplementation</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
    <masking_description>The Laboratoires Riva will provide the active vitamin D3 and placebo pills, identical in appearance, which will be pre-packaged in coded 60-pill bottles. A web-based randomisation system will allow the research personnel (RP) to log in, obtain a randomization number, and dispense study drugs, pre-prepared by the Central pharmacy, in masked kits.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in incidence of laboratory-confirmed COVID-19 infection</measure>
    <time_frame>16 weeks</time_frame>
    <description>documented by salivary or NP samples obtained clinically for screening or diagnostic purposes throughout the study period, self-obtained salivary samples at endpoint, analysed by RT-qPCR or COVID-19 seroconversion at endpoints</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Distribution of disease severity</measure>
    <time_frame>up to 16 weeks</time_frame>
    <description>5-category ordinal variable [asymptomatic, mild (managed at home); moderate (hospitalisation without supplemental oxygen; severe (oxygen supplementation); critical (mechanical ventilation/death)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of symptoms in COVID-19 positive participants</measure>
    <time_frame>up to 16 weeks</time_frame>
    <description>For asymptomatic positive COVID-19 participants, symptoms will be recorded in a daily diary up to 14 days. Symptomatic positive COVID-19 participants will record their symptoms in a daily diary up to 48 hours after the resolution of symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with COVID-19 positive IgG serology</measure>
    <time_frame>16 weeks</time_frame>
    <description>SARS-CoV-2 IgG Diasorin on Liaison XL platform</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of workday absences due to COVID-19 suspected/confirmed infection</measure>
    <time_frame>16 weeks</time_frame>
    <description>Participant-reported; reported by Direction of Human Resource (or for physicians, Direction des services professionnelles) databases</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of workday absences for any reason</measure>
    <time_frame>16 weeks</time_frame>
    <description>Participant-reported; reported by Direction of Human Resource (or for physicians, Direction des services professionnelles) databases</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse health events</measure>
    <time_frame>16 weeks</time_frame>
    <description>Number and distribution of adverse health events</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">2414</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>10 placebo tablets taken orally at baseline, followed by 1 placebo tablet once a week for 16 weeks&#xD;
Note that the study may be prolonged according to the overall infection rate monitored monthly.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vitamin D3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 tablets containing 10,000 IU (total : 100,000 IU) of Vitamin D3 taken orally at baseline, followed by 10,000 IU once a week for 16 weeks.&#xD;
Note that the study may be prolonged according to the overall infection rate monitored monthly.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Weekly oral dose of placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin D</intervention_name>
    <description>Weekly oral dose of Vitamin D</description>
    <arm_group_label>Vitamin D3</arm_group_label>
    <other_name>cholecalciferol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  are aged â‰¥18 and &lt;70 years old;&#xD;
&#xD;
          -  licenced to practice in Quebec;&#xD;
&#xD;
          -  working or scheduled to work over the next 16 weeks in a setting at high-risk of&#xD;
             contact with COVID-19 cases, particularly (but not only) those involved with aerosol&#xD;
             generating medical procedures in hospitals and caring for patients with no negative&#xD;
             pressure room (LTCF);&#xD;
&#xD;
          -  working in high COVID incidence areas;&#xD;
&#xD;
          -  covered by the RAMQ for medical services and hospitalisations;&#xD;
&#xD;
          -  has a personal email or phone (to which to send every two weeks a reminder and&#xD;
             questionnaire by email or text messages);&#xD;
&#xD;
          -  has a fixed address (to which to send the material) in the greater Montreal or&#xD;
             surrounding areas.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  vitamin D supplementation â‰¥400 IU/day or â‰¥ 12,000 IU/month in past 3 months;&#xD;
&#xD;
          -  suspected or previously documented COVID-19 infection;&#xD;
&#xD;
          -  history of nephrolithiasis, hypercalcemia, hyperphosphatemia, hyperparathyroidism,&#xD;
             granulomatosis disease (e.g., tuberculosis, sarcoidosis), renal impairment/failure,&#xD;
             active cancer, or malabsorption syndromes;&#xD;
&#xD;
          -  use of any of the following medications: lithium, thiazide or thiazide-like&#xD;
             medication, tamoxifen, amiloride, teriparatide, theophyllin, or digoxin;&#xD;
&#xD;
          -  anticipated prolonged absence from work during the study period (i.e., pregnancy);&#xD;
&#xD;
          -  enrolment in a concurrent randomized trial;&#xD;
&#xD;
          -  has received a vaccine against COVID-19.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francine M Ducharme, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Justine's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Cecile Tremblay, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHUM</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Natacha Gaulin-Marion</last_name>
    <phone>514-345-4931</phone>
    <phone_ext>7243</phone_ext>
    <email>anatacha.gaulin-marion.hsj@ssss.gouv.qc.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Amandine AugÃ©</last_name>
    <phone>514-345-4931</phone>
    <phone_ext>6196</phone_ext>
    <email>Amandine.Auge1.hsj@ssss.gouv.qc.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHUM</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2W 1T8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Cecile Tremblay, MD</last_name>
      <phone>1-514-890-8000</phone>
      <phone_ext>14645</phone_ext>
      <email>c.tremblay@umontreal.ca</email>
    </contact>
    <contact_backup>
      <last_name>Annie Chamberland</last_name>
      <phone>1-514-890-8000</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>CHU Sainte-Justine (CHUSJ)</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T1C5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Francine M Ducharme, MD, M.Sc.</last_name>
      <phone>1-514-345-4931</phone>
      <phone_ext>4398</phone_ext>
      <email>francine.m.ducharme@umontreal.ca</email>
    </contact>
    <contact_backup>
      <last_name>Annie ThÃ©oret</last_name>
      <phone>1-514-345-4931</phone>
      <phone_ext>7171</phone_ext>
      <email>annie.theoret@recherche-ste-justine.qc.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Francine M Ducharme, MD, M.Sc.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>June 29, 2020</study_first_submitted>
  <study_first_submitted_qc>July 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 23, 2020</study_first_posted>
  <last_update_submitted>November 19, 2020</last_update_submitted>
  <last_update_submitted_qc>November 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>St. Justine's Hospital</investigator_affiliation>
    <investigator_full_name>Professor Francine Ducharme</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Vitamin D</keyword>
  <keyword>Primary prevention</keyword>
  <keyword>Health care workers</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

